Stock of the Day for August 22, 2024

Bavarian Nordic A/S Stock Report

Bavarian Nordic A/S
BVNRY 90-day performance OTCMKTS:BVNRY Bavarian Nordic A/S
Current Price
$7.34
+0.12 (+1.66%)
(As of 04/1/2025 03:59 PM ET)
30 Day Performance
-4.49%
  
  
90 Day Performance
-18.77%
  
  
1 Year Performance
-5.54%
  
  
Market Capitalization
$1.73B
P/E Ratio
10.63
Net Income
$214.20M

About Bavarian Nordic A/S

Bavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.

Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.

The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.

The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. 

BVNRY Company Calendar

MAR. 5, 2025
Last Earnings
APR. 2, 2025
Today
MAY. 14, 2025
Next Earnings (Estimated)
DEC. 31, 2025
Fiscal Year End

Recent Bavarian Nordic A/S News

FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccine
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine
Short Interest in Bavarian Nordic A/S (OTCMKTS:BVNRY) Increases By 39.6%
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Bavarian Nordic A/S (BVNKF) Q4 2024 Earnings Call Transcript
This report was written by MarketBeat.com on April 2, 2025. This report first appeared on MarketBeat.com.